|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Spiro SG and Silvestri GA: One hundred
years of lung cancer. Am J Respir Crit Care Med. 172:523–529. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zheng Z, Chen T, Li X, Haura E, Sharma A
and Bepler G: DNA synthesis and repair genes RRM1 and ERCC1 in lung
cancer. N Engl J Med. 356:800–808. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Denhardt DT and Guo X: Osteopontin: a
protein with diverse functions. FASEB J. 7:1475–1482.
1993.PubMed/NCBI
|
|
5
|
Shijubo N, Kojima H, Nagata M, Ohchi T,
Suzuki A, Abe S and Sato N: Tumor angiogenesis of non-small cell
lung cancer. Microsc Res Tech. 60:186–198. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
O'Regan A: The role of osteopontin in lung
disease. Cytokine Growth Factor Rev. 14:479–488. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chambers AF, Wilson SM, Kerkvliet N,
O'Malley FP, Harris JF and Casson AG: Osteopontin expression in
lung cancer. Lung Cancer. 15:311–323. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Tierney JF, Stewart LA, Ghersi D, Burdett
S and Sydes MR: Practical methods for incorporating summary
time-to-event data into meta-analysis. Trials. 8:162007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Whitehead A and Whitehead J: A general
parametric approach to the meta-analysis of randomized clinical
trials. Stat Med. 10:1665–1677. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ioannidis JP, Patsopoulos NA and Evangelou
E: Uncertainty in heterogeneity estimates in meta-analyses. BMJ.
335:914–916. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Higgins JP, Thompson SG, Deeks JJ and
Altman DG: Measuring inconsistency in meta-analyses. BMJ.
327:557–560. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
DerSimonian R and Laird N: Meta-analysis
in clinical trials. Control Clin Trials. 7:177–188. 1986.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Mantel N and Haenszel W: Statistical
aspects of the analysis of data from retrospective studies of
disease. J Natl Cancer Inst. 22:719–748. 1959.PubMed/NCBI
|
|
14
|
Egger M, Davey Smith G, Schneider M and
Minder C: Bias in meta-analysis detected by a simple, graphical
test. BMJ. 315:629–634. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Macaskill P, Walter SD and Irwig L: A
comparison of methods to detect publication bias in meta-analysis.
Stat Med. 20:641–654. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
16
|
Weber GF, Lett GS and Haubein NC:
Osteopontin is a marker for cancer aggressiveness and patient
survival. Br J Cancer. 103:861–869. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhang L, Hou X, Lu S, et al: Predictive
significance of bone sialoprotein and osteopontin for bone
metastases in resected Chinese non-small-cell lung cancer patients:
a large cohort retrospective study. Lung Cancer. 67:114–119. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Shijubo N, Uede T, Kon S, Maeda M, Segawa
T, Imada A, Hirasawa M and Abe S: Vascular endothelial growth
factor and osteopontin in stage I lung adenocarcinoma. Am J Respir
Crit Care Med. 160:1269–1273. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Donati V, Boldrini L, Dell'Omodarme M,
Prati MC, Faviana P, Camacci T, Lucchi M, Mussi A, Santoro M,
Basolo F and Fontanini G: Osteopontin expression and prognostic
significance in non-small cell lung cancer. Clin Cancer Res.
11:6459–6465. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Boldrini L, Donati V, Dell'Omodarme M,
Prati MC, Faviana P, Camacci T, Lucchi M, Mussi A, Santoro M,
Basolo F and Fontanini G: Prognostic significance of osteopontin
expression in early-stage non-small-cell lung cancer. Br J Cancer.
93:453–457. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Le QT, Chen E, Salim A, et al: An
evaluation of tumor oxygenation and gene expression in patients
with early stage non-small cell lung cancers. Clin Cancer Res.
12:1507–1514. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Mack PC, Redman MW, Chansky K, Williamson
SK, Farneth NC, Lara PN Jr, Franklin WA, Le QT, Crowley JJ and
Gandara DR: SWOG Lower osteopontin plasma levels are associated
with superior outcomes in advanced non-small-cell lung cancer
patients receiving platinum-based chemotherapy: SWOG Study S0003. J
Clin Oncol. 26:4771–4776. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Schneider S, Yochim J, Brabender J, Uchida
K, Danenberg KD, Metzger R, Schneider PM, Salonga D, Hölscher AH
and Danenberg PV: Osteopontin but not osteonectin messenger RNA
expression is a prognostic marker in curatively resected non-small
cell lung cancer. Clin Cancer Res. 10:1588–1596. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Takenaka M, Hanagiri T, Shinohara S, et
al: Serum level of osteopontin as a prognostic factor in patients
who underwent surgical resection for non-small-cell lung cancer.
Clin Lung Cancer. 14:288–294. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Isa S, Kawaguchi T, Teramukai S, et al:
Serum osteopontin levels are highly prognostic for survival in
advanced non-small cell lung cancer: results from JMTO LC 0004. J
Thorac Oncol. 4:1104–1110. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Albain KS, Barlow WE, Shak S, et al:
Prognostic and predictive value of the 21-gene recurrence score
assay in postmenopausal women with node-positive,
estrogen-receptor-positive breast cancer on chemotherapy: a
retrospective analysis of a randomised trial. Lancet Oncol.
11:55–65. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lièvre A, Bachet JB, Boige V, et al: KRAS
mutations as an independent prognostic factor in patients with
advanced colorectal cancer treated with cetuximab. J Clin Oncol.
26:374–379. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kratz JR, He J, Van Den Eeden SK, et al: A
practical molecular assay to predict survival in resected
non-squamous, non-small-cell lung cancer: development and
international validation studies. Lancet. 379:823–832. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Rangaswami H, Bulbule A and Kundu GC:
Osteopontin: role in cell signaling and cancer progression. Trends
Cell Biol. 16:79–87. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Goparaju CM, Pass HI, Blasberg JD, Hirsch
N and Donington JS: Functional heterogeneity of osteopontin
isoforms in non-small cell lung cancer. J Thorac Oncol.
5:1516–1523. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Rahbari NN, Aigner M, Thorlund K, et al:
Meta-analysis shows that detection of circulating tumor cells
indicates poor prognosis in patients with colorectal cancer.
Gastroenterology. 138:1714–1726. 2010. View Article : Google Scholar : PubMed/NCBI
|
